CN103142559A - Risperidone film-like preparation - Google Patents
Risperidone film-like preparation Download PDFInfo
- Publication number
- CN103142559A CN103142559A CN2013100564457A CN201310056445A CN103142559A CN 103142559 A CN103142559 A CN 103142559A CN 2013100564457 A CN2013100564457 A CN 2013100564457A CN 201310056445 A CN201310056445 A CN 201310056445A CN 103142559 A CN103142559 A CN 103142559A
- Authority
- CN
- China
- Prior art keywords
- film band
- strip film
- risperidone
- acid
- alkaline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention provides a risperidone film-like preparation, comprising a strip film belt and a treatment effective dose of an active medicine loratadine loaded on the strip film belt, wherein the strip film belt comprises an acidic strip film belt and an alkaline strip film belt, the acidic strip film belt and the alkaline strip film belt are connected to form one body, the acidic strip film belt uses a highly water-soluble polymer film forming material as a main body and contains 1 to 20% of an acidic agent on the basis of the weight of the acidic strip film belt, and the alkaline strip film belt uses the highly water-soluble polymer film forming material as a main body and contains 1 to 20% by weight of an alkaline agent on the basis of the weight of the alkaline strip film belt. In the presence of water, the risperidone film-like preparation provided by the invention becomes an effervescent film, generates considerable bubbles, paralyzes olfactory sensation of people so as to mask odor and is accelerated in dissolving-out.
Description
Technical field
The present invention relates to the risperidone preparation, be specifically related to contain the medicine film preparation of risperidone.
Background technology
Risperidone is the benzisoxa oxazole derivatives, is the psychosis of a new generation.It is a kind of selectivity monoaminergic antagonist with peculiar property, with the 5-HT of 5-hydroxy tryptamine energy
2The D of receptor and dopamine
2Receptor has very high affinity.Be used for the treatment of the obvious positive symptom (as hallucination, illusion, disturbance in thinking, be hostile to, suspect) of acute and chronic schizophrenia and other various psychotic disease states and obvious negative symptoms (as indifferent, hypologia in bradykinesia, amorphous type and social activity).Also can alleviate the emotion symptom relevant with schizophrenia (as: depression, sense of guilt, anxiety).For the effective patient of acute stages treated, in the maintenance phase treatment, can continue to bring into play its clinical efficacy.Risperidone preparation is become the medicine film preparation, need use water delivery service, be placed on tongue instantly, can improve patient's compliance, be subject to patient's welcome; And its production technology is simple, and power consumption is few, and cost is lower.
The medicine film preparation is as far back as i.e. existing many researchs of nineteen seventies, as tranquilizer film (Chinese Journal of Pharmaceuticals, 1976,12(19)), diphenoxylate medicine film (Chinese Journal of Pharmaceuticals, 1976,12(22)), external applied contraceptive film (Chinese Journal of Pharmaceuticals, 1977,4-5(45)), nitroglycerin medicine film (Chinese Journal of Pharmaceuticals, 1977,12(5)), rhodexin film (Chinese Journal of Pharmaceuticals, 1980,4(18)), clonidine sustained release film formulation (Chinese Journal of Pharmaceuticals, 1981,3(141)) etc.Chinese Pharmacopoeia is also recorded (Pharmacopoeia of People's Republic of China 1995 editions, 2000 editions, 2005 editions, 2010 editions) to membrane as official preparation.
Yet membrane is thin, light, little, the easy moisture absorption, thereby to having relatively high expectations of packing, should be easy to use, should be able to guarantee again the quality of medicine, and domestic present packaged form uses inconvenience, not attractive in appearance; The drug loading of membrane not high (general 30～60mg is following), and to carry out taste masking.These have all restricted development and the application of membrane.
In recent years, membrane development is swift and violent, and calendar year 2001 Pfizer company has released
With
Product is used for anti-halitosis in advance.Novartis company has also released folk prescription or the compound oral membrane that a series of effective ingredient are diphenhydramine, phenylephrine and dextromethorphan, is used for prevention and the treatment of flu, cough or rhinitis.There is subsequently more pelliculae pro cavo oris product to occur.Biofilm company is used for the pelliculae pro cavo oris technology product of physical strength reinforcing, vitimin supplement, hypersexuality and appetite-suppressing.Ondansetron (ondansetron) membrane and its oral cavity quick disintegrating slice (Zofran of the exploitation of MonosolRx company
) bioequivalence, obtain the approval of FDA in July, 2010.Passion for Life Healthcare company develops and the product of the prevention of a kind of uniqueness of having gone on the market snoring
Voglibose (voglibose) membrane of Japan Kyukyu yakuhin Kogyo K.K. development was released in August, 2006, was used for improving the diabetics postprandial hyperglycemia.
patent about membrane also emerges in an endless stream, the edible water-soluble film (CN101516331A) that contains foam reducing flavoring agent is arranged, the film bandage (CN101389309A) that is used for mucosal administration of actives, high dose film compositions and preparation method thereof (CN101616660A), polymer-based films and drug delivery system prepared therefrom (CN101668519A), the preparation method of edible film (CN101744791A), the film (CN101346135A) that is used for the adjusted pH that activating agent sends, the film bandage (CN101389309A) that is used for mucosal administration of actives, non-mucoadhesive film dosage forms (CN101626756A), disintegrable oral films (CN101384249A), membrane that can be Orally administered (CN101621990A), be used for neuroleptic, the oral fast that can not be spued collapses film (CN101287445A), instant capacity membrane (CN100396332C) etc.The inventor has also applied for the patent of new packaged form of packaging machine, the membrane of production machine, the membrane of membrane, to promote membrane development at home.
The inventor usually runs into following two problems in the R﹠D process of membrane:
1) active constituents of medicine usually has bitterness, needs taste masking.Adding effervescent is a kind of known comparatively effectively method to modify taste, effervescent is comprised of acidizer (as citric acid, tartaric acid, fumaric acid, adipic acid and malic acid etc.) and alkaline agent (as sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate and calcium carbonate etc.), after entry, both react, produce a large amount of carbon dioxide, it can temporarily benumb taste bud and taste masking.But in the process of preparation membrane, normally adjuvant is scattered in aqueous solvent together with active constituents of medicine, repastes the cloth drying and forming-film.Acidizer in effervescent and alkaline agent react in the with slurry process, can't retain in film simultaneously.When 2) preparing the compound recipe membrane, because the physicochemical property of the active component in compound recipe is different, the prescription and the technique that are fit to are different, influence each other sometimes.The compound recipe that for example is comprised of A and B, acidic excipient can strengthen the stability of A material, has but affected the dissolubility of B material, makes B be difficult for being uniformly dispersed in pulping process.
Summary of the invention
The purpose of this invention is to provide the membranaceous preparation of a kind of risperidone, the defective that exists to overcome prior art satisfies clinical needs.
The membranaceous preparation of described risperidone comprises the active medicine loratadine of strip film band and load treatment effective dose thereon;
Described strip film band comprises acid strip film band and alkaline strip film band, and described acid strip film band and alkaline strip film band are connected, and the space arranges; Described space arranges, and refers to when being provided with many acid strip film bands and alkaline strip film band acid strip film band and the space setting of alkaline strip film band;
Described acid strip film band take the highly-water-soluble macromolecule filming material as main body, with film band weighing scale, contains 1～20%, preferred 2～10% acidizer, and described acidizer is selected from citric acid, tartaric acid, fumaric acid, maleic acid, adipic acid or malic acid;
Described alkaline strip film band take the highly-water-soluble macromolecule filming material as main body, with film band weighing scale, contains 1～20%, preferred 2～10% alkaline agent, and described alkaline agent is selected from sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate or calcium carbonate;
Described risperidone loads on acid strip film band, also can load on alkaline strip film band, also can load on simultaneously on acid strip film band and alkaline strip film band;
Preferably, described acid strip film band and alkaline strip film band also comprise more than one in plasticizer, correctives, coloring agent or stabilizing agent;
Preferably, described acid strip film band comprises the component of following percentage by weight:
Highly-water-soluble macromolecule filming material 40～98%, preferred 50～75%;
Stabilizing agent 0～5%, preferred 0～1%;
Described alkaline strip film band comprises the component of following percentage by weight:
Highly-water-soluble macromolecule filming material 40～98%, preferred 50～75%;
Stabilizing agent 0～5%, preferred 0～1%;
In the gross weight of described membranaceous preparation, the content of described risperidone is 1～30%, preferred 5～30%;
Described membranaceous preparation thickness is 0.04～0.20mm, preferred 0.06～0.10mm;
The invention still further relates to the membranaceous preparation of risperidone that another kind is provided with blank tape, the described membranaceous preparation of risperidone that is provided with blank tape, also comprise blank tape, described blank tape is arranged between described acid strip film band and alkaline strip film band, and be connected with described acid strip film band and alkaline strip film band respectively, described blank tape comprises the highly-water-soluble macromolecule filming material;
Described risperidone loads on more than one in acid strip film band, blank tape or alkaline strip film band;
Preferably, described blank tape also comprises more than one in sharp plasticizer, correctives, coloring agent or stabilizing agent;
Described water soluble polymer filmogen comprises more than one in polyvinyl alcohol (PVA), hydroxypropyl emthylcellulose (HPMC), hydroxypropyl cellulose (HPC), polyvinylpyrrolidone (PVP), sodium alginate, CMC-Na, polyoxyethylene (PEO), Bletilla glucomannan, maltodextrin, corn starch or carrageenan;
Described acidizer is selected from citric acid, tartaric acid, fumaric acid, maleic acid, adipic acid or malic acid;
Described alkaline agent is selected from sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate or calcium carbonate;
Described plasticizer comprises more than one in Polyethylene Glycol (PEG), glycerol or Tween 80;
Described correctives comprises more than one in sweeting agent, acidic flavoring agent, aromatic, resin macromolecular material, lecithin, cephalin or phosphatidic acid etc.;
Described stabilizing agent is selected from sodium sulfite, sodium sulfite, EDTA-2Na, BHA, BHT or vitamin E etc.;
Described coloring agent is selected from titanium dioxide, various natural pigment or artificial color etc.;
Preferably:
Described acid strip film band comprises the component of following percentage by weight:
Highly-water-soluble macromolecule filming material 40～98%, preferred 50～75%;
Stabilizing agent 0～5%, preferred 0～1%;
Described alkaline strip film band comprises the component of following percentage by weight:
Highly-water-soluble macromolecule filming material 40～98%, preferred 50～75%;
Stabilizing agent 0～5%, preferred 0～1%;
Described blank tape comprises the component of following percentage by weight:
Highly-water-soluble macromolecule filming material 60～100%, preferred 70～99%;
Stabilizing agent 0～5%, preferred 0～1%;
In the gross weight of described membranaceous preparation, the content of described risperidone is 1～30%.
The preparation method of the membranaceous preparation of described risperidone comprises the steps:
(1) risperidone, acidizer and other adjuvants are mixed with water, the acquisition weight concentration is 15～35% water slip, makes acid serosity A;
(2) risperidone, alkaline agent and other adjuvants are mixed with water, the acquisition weight concentration is 15～35% water slip, makes alkaline slurry B;
(3) serosity A and serosity B are coated on flat board at the interval successively, due to the solvent expansion effect, are complex as a whole, obtain the medicine carrying thin film;
Term " interval coating successively " refers to, and one is serosity A, and other one is serosity B;
(4) the medicine carrying thin film that step (3) is obtained, dry 5～30min, obtain described membranaceous preparation at the temperature of 50～90 ℃.
Further, comprise the preparation method of the membranaceous preparation of risperidone of blank tape, comprise the steps:
(1) risperidone, acidizer and other adjuvants are mixed with water, the acquisition weight concentration is 15～35% water slip, makes acid serosity A;
(2) risperidone, alkaline agent and other adjuvants are mixed with water, the acquisition weight concentration is 15～35% water slip, makes alkaline slurry B;
(3) risperidone and other adjuvants are mixed with water, the acquisition weight concentration is 15～35% water slip, makes blank serosity C;
(3) serosity A, serosity B and blank serosity C are coated on flat board at the interval successively, due to the solvent expansion effect, are complex as a whole, obtain the medicine carrying thin film;
(4) the medicine carrying thin film that step (3) is obtained, dry 5～30min, obtain described compound membranaceous preparation at the temperature of 50～90 ℃.
Need to prove, when the content of a certain component is 0, during preparation, namely do not add.
The using method of membranaceous preparation of the present invention is identical with conventional membrane.
The beneficial effect of membranaceous preparation of the present invention is:
The inventor is coated with two or more by a large amount of experiment accumulation simultaneously when coating, finally form more than one compound membrane.Many film can be realized following specific purposes: make the effervescent film: contain the acidizers such as citric acid, tartaric acid in a film, article one, contain the alkaline agents such as sodium carbonate, sodium bicarbonate or calcium carbonate in film, become the effervescent film after chance water, produce a large amount of bubbles, benumb olfactory sensation and taste masking, and can accelerate stripping.Many film also can be rendered as double-colored or polychrome film, during especially for children preparation, increases the aesthetic feeling of medicine, improves the interest that the child takes medicine.
Description of drawings
Fig. 1 is the membranaceous preparation structure schematic diagram of risperidone.
Fig. 2 is the membranaceous preparation structure schematic diagram of risperidone with blank tape.
Fig. 3 is the risperidone film stripping curve of embodiment 1.
Fig. 4 is the risperidone film stripping curve of embodiment 2.
Fig. 5 is the risperidone film stripping curve of embodiment 5.
Fig. 6 is the risperidone film stripping curve of embodiment 6.
The specific embodiment
Referring to Fig. 1, the membranaceous preparation of described risperidone comprises acid strip film band 1 and alkaline strip film band 2, and described acid strip film band 1 and alkaline strip film band 2 are connected, and the space arranges.
Referring to Fig. 2, preferred, the membranaceous preparation of described risperidone also comprises blank tape 3, and described blank tape 3 is arranged between described acid strip film band 1 and alkaline strip film band 2, and is connected with described acid strip film band 1 and alkaline strip film band 2 respectively.
1) get risperidone 30g adding distil water 600ml, stir, be uniformly dispersed, then add successively citric acid 20g while stirring, sucralose 20g and light blue 0.2g, add at last PEO130g, stir, cross 80 mesh sieves, remove insoluble matter, vacuum defoamation.Get serosity A.
2) get risperidone 30g adding distil water 600ml, stir, be uniformly dispersed, then add successively sodium carbonate 20g while stirring, sucralose 20g and light blue 0.2g, add at last PEO130g, stir, cross 80 mesh sieves, remove insoluble matter, vacuum defoamation.Get serosity B.
Serosity A and serosity B are added in dosing tank, and this dosing tank is comprised of two parallel sulculuses, and width is 1.2cm, and the spacer width between sulculus is 0.1cm.Start the coating drying machine, with coating blade coating, the extension of film liquid on stainless steel band, 50 ℃ of dry 15min, due to the solvent expansion effect, 2 serosity are complex as a whole, and obtain the medicine carrying thin film; Adopt again the knurling rolls embossing, according to the assay result, after cutting into certain size, peel off from stainless steel band, pack and get final product.Its structure as shown in Figure 1.
The medicine film preparation that obtains, thickness is 0.06mm, can make 3 specifications: every contains risperidone 1mg, 2mg or 3mg.Adult's every day 1 time or every day 2 times.Recommending initial dose is a 1mg, and 2 times on the one, second day is increased to 2mg one time, 2 times on the one; If tolerance rose to 3mg one time, 2 times on the one on the 3rd day.After this, can keep this dosage constant or further adjust according to the personal considerations.
This medicine film preparation is aesthetic in appearance.Become the effervescent film after meeting water, produce a large amount of bubbles, stripping is rapid, and sense of taste is better.
Get 6 of this product, each clip becomes the thin film of 1cm * 1cm size, the stainless steel silk folder that is 2.0mm with two-layer sieve aperture internal diameter respectively, check according to the method (two appendix X A of Chinese Pharmacopoeia version in 2010) under disintegration inspection technique tablet item, observe and record that membrane all dissolves and the time by screen cloth.It is very fast that this product is dissolved the time limit, is 33 ± 3s.
Get 6 of this product, clamp with paperclip respectively, adopt dissolution method (two appendix X C three therapeutic methods of traditional Chinese medicine of Chinese Pharmacopoeia version in 2010) device, take water 100ml as dissolution medium, rotating speed is per minute 50 to turn, from test sample contact dissolution medium, timing immediately is respectively in the time of 30 seconds, 1,2,3,5 and 10 minute, get solution 1ml, filter, get subsequent filtrate, measure and calculate the stripping quantity of every according to high performance liquid chromatography (two appendix V D of Chinese Pharmacopoeia version in 2010).Its In Vitro Dissolution curve is seen Fig. 3.As seen from Figure 3, the In Vitro Dissolution of risperidone film of the present invention is very fast, dissolve complete during 2min.
1) get risperidone 20g adding distil water 600ml, stir, be uniformly dispersed, add successively while stirring again PEG400010g, fumaric acid 10g, BHT0.2g, saccharin sodium 10g and titanium dioxide 10g, add at last PVP40g and HPMC100g, stir, cross 80 mesh sieves, remove insoluble matter, vacuum defoamation.Get serosity A.
2) get risperidone 20g adding distil water 600ml, stir, be uniformly dispersed, add successively while stirring again PEG400010g, potassium bicarbonate 10g, BHT0.2g, saccharin sodium 10g and titanium dioxide 10g, add at last PVP40g and HPMC100g, stir, cross 80 mesh sieves, remove insoluble matter, vacuum defoamation.Get serosity B.
Serosity A and serosity B are added in dosing tank, and this dosing tank is comprised of two parallel sulculuses, and width is 1.2cm, and the spacer width between sulculus is 0.1cm.Start the coating drying machine, with coating blade coating, the extension of film liquid on stainless steel band, 90 ℃ of dry 5min, due to the solvent expansion effect, 2 serosity are complex as a whole, and obtain the medicine carrying thin film; Adopt again the knurling rolls embossing, according to the assay result, after cutting into certain size, peel off from stainless steel band, pack and get final product.Its structure as shown in Figure 1.
The medicine film preparation that obtains, thickness is 0.07mm, can make 3 specifications: every contains risperidone 1mg, 2mg or 3mg.Adult's every day 1 time or every day 2 times.Recommending initial dose is a 1mg, and 2 times on the one, second day is increased to 2mg one time, 2 times on the one; If tolerance rose to 3mg one time, 2 times on the one on the 3rd day.After this, can keep this dosage constant or further adjust according to the personal considerations.
This medicine film preparation is aesthetic in appearance.Become the effervescent film after meeting water, produce a large amount of bubbles, stripping is rapid, and sense of taste is better.
Get 6 of this product, each clip becomes the thin film of 1cm * 1cm size, the stainless steel silk folder that is 2.0mm with two-layer sieve aperture internal diameter respectively, check according to the method (two appendix X A of Chinese Pharmacopoeia version in 2010) under disintegration inspection technique tablet item, observe and record that membrane all dissolves and the time by screen cloth.It is very fast that this product is dissolved the time limit, is 39 ± 4s.
Get 6 of this product, clamp with paperclip respectively, adopt dissolution method (two appendix X C three therapeutic methods of traditional Chinese medicine of Chinese Pharmacopoeia version in 2010) device, take water 100ml as dissolution medium, rotating speed is per minute 50 to turn, from test sample contact dissolution medium, timing immediately is respectively in the time of 30 seconds, 1,2,3,5 and 10 minute, get solution 1ml, filter, get subsequent filtrate, measure and calculate the stripping quantity of every according to high performance liquid chromatography (two appendix V D of Chinese Pharmacopoeia version in 2010).Its In Vitro Dissolution curve is seen Fig. 4.As seen from Figure 4, the In Vitro Dissolution of risperidone film of the present invention is very fast, dissolve complete during 2min.
1) get risperidone 10g adding distil water 500ml, dispersed with stirring is even, add while stirring again aspartame 10g, cyclamate 20g, glycerol 6g, EDTA0.2g, lemon yellow 0.2g and tartaric acid 4g, add at last HPC100g and maltodextrin 50g, stir, cross 80 mesh sieves, remove insoluble matter, vacuum defoamation.Get serosity A.
2) get risperidone 10g adding distil water 500ml, dispersed with stirring is even, add while stirring again aspartame 10g, cyclamate 20g, glycerol 6g, EDTA0.2g, lemon yellow 0.2g and potassium carbonate 4g, add at last HPC100g and maltodextrin 50g, stir, cross 80 mesh sieves, remove insoluble matter, vacuum defoamation.Get serosity B.
Serosity A and serosity B are added in dosing tank, and this dosing tank is comprised of two parallel sulculuses, and width is 1.2cm, and the spacer width between sulculus is 0.1cm.Start the coating drying machine, with coating blade coating, the extension of film liquid on stainless steel band, 70 ℃ of dry 30min, due to the solvent expansion effect, 2 serosity are complex as a whole, and obtain the medicine carrying thin film; Adopt again the knurling rolls embossing, according to the assay result, after cutting into certain size, peel off from stainless steel band, pack and get final product.Its structure as shown in Figure 1.
The medicine film preparation that obtains, thickness is 0.09mm, can make 3 specifications: every contains risperidone 1mg, 2mg or 3mg.Adult's every day 1 time or every day 2 times.Recommending initial dose is a 1mg, and 2 times on the one, second day is increased to 2mg one time, 2 times on the one; If tolerance rose to 3mg one time, 2 times on the one on the 3rd day.After this, can keep this dosage constant or further adjust according to the personal considerations.
This medicine film preparation is aesthetic in appearance.Become the effervescent film after meeting water, produce a large amount of bubbles, stripping is rapid, and sense of taste is better.
Get 6 of this product, each clip becomes the thin film of 1cm * 1cm size, the stainless steel silk folder that is 2.0mm with two-layer sieve aperture internal diameter respectively, check according to the method (two appendix X A of Chinese Pharmacopoeia version in 2010) under disintegration inspection technique tablet item, observe and record that membrane all dissolves and the time by screen cloth.It is very fast that this product is dissolved the time limit, is 45 ± 4s.
Embodiment 4
1) get risperidone 60g adding distil water 600ml, stir, be uniformly dispersed, then add while stirring aspartame 15g, titanium dioxide 10g, EDTA0.1g and and maleic acid 15g, add at last PVA100g, stir, cross 80 mesh sieves, remove insoluble matter, vacuum defoamation.Get serosity A.
2) get risperidone 60g adding distil water 600ml, stir, be uniformly dispersed, add while stirring again aspartame 15g, titanium dioxide 10g, EDTA0.1g and and sodium bicarbonate 15g, add at last PVA100g, stir, cross 80 mesh sieves, remove insoluble matter, vacuum defoamation.Get serosity B.
Serosity A and serosity B are added in dosing tank, and this dosing tank is comprised of two parallel sulculuses, and width is 1.2cm, and the spacer width between sulculus is 0.1cm.Start the coating drying machine, with coating blade coating, the extension of film liquid on stainless steel band, 80 ℃ of dry 20min, due to the solvent expansion effect, 2 serosity are complex as a whole, and obtain the medicine carrying thin film; Adopt again the knurling rolls embossing, according to the assay result, after cutting into certain size, peel off from stainless steel band, pack and get final product.Its structure as shown in Figure 1.
The medicine film preparation that obtains, thickness is 0.06mm, can make 3 specifications: every contains risperidone 1mg, 2mg or 3mg.Adult's every day 1 time or every day 2 times.Recommending initial dose is a 1mg, and 2 times on the one, second day is increased to 2mg one time, 2 times on the one; If tolerance rose to 3mg one time, 2 times on the one on the 3rd day.After this, can keep this dosage constant or further adjust according to the personal considerations.
This medicine film preparation is aesthetic in appearance.Become the effervescent film after meeting water, produce a large amount of bubbles, stripping is rapid, and sense of taste is better.
Get 6 of this product, each clip becomes the thin film of 1cm * 1cm size, the stainless steel silk folder that is 2.0mm with two-layer sieve aperture internal diameter respectively, check according to the method (two appendix X A of Chinese Pharmacopoeia version in 2010) under disintegration inspection technique tablet item, observe and record that membrane all dissolves and the time by screen cloth.It is very fast that this product is dissolved the time limit, is 32 ± 3s.
Embodiment 5
The risperidone film
1) get risperidone 30g adding distil water 600ml, stir, be uniformly dispersed, add while stirring again PEG40010g, malic acid 20g, sucralose 10g and erythrosine pigment 0.3g, add at last PVA100g and corn starch 30g, cross 80 mesh sieves, remove insoluble matter, vacuum defoamation.Get serosity A.
2) get risperidone 2g, adding distil water 100ml is uniformly dispersed, then adds allured red pigment 0.3g and sunset yellow 0.6g, adds at last PVA31g, stirs, and crosses 80 mesh sieves, removes insoluble matter, vacuum defoamation.Get serosity B.
3) get risperidone 30g adding distil water 600ml, stir, be uniformly dispersed, add while stirring again PEG40010g, calcium carbonate 20g, sucralose 10g and erythrosine pigment 0.3g, add at last PVA100g and corn starch 30g, cross 80 mesh sieves, remove insoluble matter, vacuum defoamation.Get serosity C.
Serosity A, B and C are added in dosing tank, and this dosing tank is comprised of three parallel sulculuses, and width is respectively 1.2,0.2,1.2cm, and the spacer width between sulculus is 0.1cm.Start the coating drying machine, with coating blade coating, the extension of film liquid on stainless steel band, 60 ℃ of dry 10min, due to the solvent expansion effect, 3 serosity are complex as a whole, and obtain the medicine carrying thin film; Adopt again the knurling rolls embossing, according to the assay result, after cutting into certain size, peel off from stainless steel band, pack and get final product.Its structure as shown in Figure 2.
The medicine film preparation that obtains, thickness is 0.06mm, can make 3 specifications: every contains risperidone 1mg, 2mg or 3mg.Adult's every day 1 time or every day 2 times.Recommending initial dose is a 1mg, and 2 times on the one, second day is increased to 2mg one time, 2 times on the one; If tolerance rose to 3mg one time, 2 times on the one on the 3rd day.After this, can keep this dosage constant or further adjust according to the personal considerations.
This film preparation is comprised of trichroism, and is aesthetic in appearance, becomes the effervescent film after chance water, produces a large amount of bubbles, and stripping is rapid, and sense of taste is better.
Get 6 of this product, each clip becomes the thin film of 1cm * 1cm size, the stainless steel silk folder that is 2.0mm with two-layer sieve aperture internal diameter respectively, check according to the method (two appendix X A of Chinese Pharmacopoeia version in 2010) under disintegration inspection technique tablet item, observe and record that membrane all dissolves and the time by screen cloth.The dissolving time limit of risperidone film of the present invention is very fast, is 31 ± 3s.
Get 6 of this product, clamp with paperclip respectively, adopt dissolution method (two appendix X C three therapeutic methods of traditional Chinese medicine of Chinese Pharmacopoeia version in 2010) device, take water 100ml as dissolution medium, rotating speed is per minute 50 to turn, from test sample contact dissolution medium, timing immediately is respectively in the time of 30 seconds, 1,2,3,5 and 10 minute, get solution 1ml, filter, get subsequent filtrate, measure and calculate the stripping quantity of every according to high performance liquid chromatography (two appendix V D of Chinese Pharmacopoeia version in 2010).Its In Vitro Dissolution curve is seen Fig. 5.As seen from Figure 5, the In Vitro Dissolution of risperidone film of the present invention is very fast, dissolve complete during 2min.
The risperidone film
1) get risperidone 20g adding distil water 600ml, stir, be uniformly dispersed, add while stirring again PEG20004g, citric acid 10g, stevioside 10g and allured red pigment 0.3g, add at last HPC156g, stir, cross 80 mesh sieves, remove insoluble matter, vacuum defoamation.Get serosity A;
2) get HPC33g adding distil water 100ml, stir, then add allured red pigment 0.1g and sunset yellow 0.2g, stir, cross 80 mesh sieves, remove insoluble matter, vacuum defoamation.Get serosity B;
3) get risperidone 20g adding distil water 600ml, stir, be uniformly dispersed, then add PEG20004g while stirring, sodium bicarbonate 10g, stevioside 10g and allured red pigment 0.3g, add at last HPC156g, cross 80 mesh sieves, remove insoluble matter, vacuum defoamation.Get serosity C.
Serosity A, B and C are added in dosing tank, and this dosing tank is comprised of three parallel sulculuses, and width is respectively 1.2,0.2,1.2cm, and the spacer width between sulculus is 0.1cm.Start the coating drying machine, with coating blade coating, the extension of film liquid on stainless steel band, 80 ℃ of dry 10min, due to the solvent expansion effect, 3 serosity are complex as a whole, and obtain the medicine carrying thin film; Adopt again the knurling rolls embossing, according to the assay result, after cutting into certain size, peel off from stainless steel band, pack and get final product.Its structure as shown in Figure 2.
The medicine film preparation that obtains, thickness is 0.07mm, can make 3 specifications: every contains risperidone 1mg, 2mg or 3mg.Adult's every day 1 time or every day 2 times.Recommending initial dose is a 1mg, and 2 times on the one, second day is increased to 2mg one time, 2 times on the one; If tolerance rose to 3mg one time, 2 times on the one on the 3rd day.After this, can keep this dosage constant or further adjust according to the personal considerations.
This film preparation is comprised of trichroism, and is aesthetic in appearance, becomes the effervescent film after chance water, produces a large amount of bubbles, and stripping is rapid, and sense of taste is better.
Get 6 of this product, each clip becomes the thin film of 1cm * 1cm size, the stainless steel silk folder that is 2.0mm with two-layer sieve aperture internal diameter respectively, check according to the method (two appendix X A of Chinese Pharmacopoeia version in 2010) under disintegration inspection technique tablet item, observe and record that membrane all dissolves and the time by screen cloth.The dissolving time limit of risperidone film of the present invention is very fast, is 38 ± 4s.
Get 6 of this product, clamp with paperclip respectively, adopt dissolution method (two appendix X C three therapeutic methods of traditional Chinese medicine of Chinese Pharmacopoeia version in 2010) device, take water 100ml as dissolution medium, rotating speed is per minute 50 to turn, from test sample contact dissolution medium, timing immediately is respectively in the time of 30 seconds, 1,2,3,5 and 10 minute, get solution 1ml, filter, get subsequent filtrate, measure and calculate the stripping quantity of every according to high performance liquid chromatography (two appendix V D of Chinese Pharmacopoeia version in 2010).Its In Vitro Dissolution curve is seen Fig. 6.As seen from Figure 6, the In Vitro Dissolution of risperidone film of the present invention is very fast, dissolve complete during 2min.
Embodiment 7
1) get risperidone 40g adding distil water 600ml, stir, be uniformly dispersed, then add while stirring xylitol 18g, light blue 0.2g, tartaric acid 20g and vitamin E2 g, add at last HPMC120g, stir, cross 80 mesh sieves, remove insoluble matter, vacuum defoamation.Get serosity A.
2) get risperidone 5g adding distil water 100ml, stir, be uniformly dispersed, then add while stirring xylitol 5g and light blue 0.03g, add at last HPMC18g and maltodextrin 5g, stir, cross 80 mesh sieves, remove insoluble matter, vacuum defoamation.Get serosity B.
3) get HPMC60g and CMC-Na20g adding distil water 300ml, stir, then add potassium carbonate 20g and erythrosine 0.1g, stir, cross 80 mesh sieves, remove insoluble matter, vacuum defoamation.Get serosity C.
Serosity A, B, C are added in dosing tank, and this dosing tank is comprised of three parallel sulculuses, and width is respectively 1.2cm, 0.2cm and 0.6cm, and the spacer width between sulculus is 0.1cm.Start the coating drying machine, with coating blade coating, the extension of film liquid on stainless steel band, 60 ℃ of dry 10min, due to the solvent expansion effect, 2 serosity are complex as a whole, and obtain the medicine carrying thin film; Adopt again the knurling rolls embossing, according to the assay result, after cutting into certain size, peel off from stainless steel band, pack and get final product.Its structure as shown in Figure 2.
The medicine film preparation that obtains, thickness is 0.06mm, can make 3 specifications: every contains risperidone 1mg, 2mg or 3mg.Adult's every day 1 time or every day 2 times.Recommending initial dose is a 1mg, and 2 times on the one, second day is increased to 2mg one time, 2 times on the one; If tolerance rose to 3mg one time, 2 times on the one on the 3rd day.After this, can keep this dosage constant or further adjust according to the personal considerations.
This medicine film preparation is aesthetic in appearance.Become the effervescent film after meeting water, produce a large amount of bubbles, stripping is rapid, and sense of taste is better.
Get 6 of this product, each clip becomes the thin film of 1cm * 1cm size, and the stainless steel silk folder that is 2.0mm with two-layer sieve aperture internal diameter respectively shines method (two appendix X A of Chinese Pharmacopoeia version in the 2010) inspection under inspection technique tablet item disintegration,
Observe and record that membrane all dissolves and the time by screen cloth.It is very fast that this product is dissolved the time limit, is 32 ± 3s.
Get the film of embodiment 1 and embodiment 5, carry out high temperature, high humidity and exposure experiments to light, investigate the stability of sample.
Hot test: film is removed packing put in culture dish, placed 10 days under 60 ℃ of conditions, in the 5th day and sampling in the 10th day, detect content, related substance and the dissolution of risperidone in film.
High wet test: film is removed packing put in culture dish, placed 10 days under relative humidity 75% condition at 25 ℃, in the 5th day and sampling in the 10th day, detect content, related substance and the dissolution of risperidone in film.
Exposure experiments to light: film being removed packing put in culture dish, is to place 10 days under the condition of 4500Lx ± 500Lx in illumination, in the 5th day and sampling in the 10th day, and content, related substance and the dissolution of risperidone in the detection film.
Testing result sees Table 1～table 2.
Table 1 embodiment 1 stability sample quality inspection result
Hot test (60 ℃) sample quality assay
High wet test (25 ℃, 75%RH) sample quality assay
Exposure experiments to light (4500Lx) sample quality assay
As shown in Table 1, the risperidone film of this prescription and technique preparation is all stable under high temperature, high humidity and illumination condition.
Table 2 embodiment 5 stability sample quality inspection results
Hot test (60 ℃) sample quality assay
High wet test (25 ℃, 75%RH) sample quality assay
Exposure experiments to light (4500Lx) sample quality assay
As shown in Table 2, the risperidone film of this prescription and technique preparation is all stable under high temperature, high humidity and illumination condition.
Claims (12)
1. the membranaceous preparation of risperidone, is characterized in that, comprises the active medicine loratadine of strip film band and load treatment effective dose thereon;
Described strip film band comprises acid strip film band and alkaline strip film band, and described acid strip film band and alkaline strip film band are connected;
Described acid strip film band take the highly-water-soluble macromolecule filming material as main body, with film band weighing scale, contains 1～20% acidizer;
Described alkaline strip film band take the highly-water-soluble macromolecule filming material as main body, with film band weighing scale, contains 1～20% alkaline agent.
2. the membranaceous preparation of risperidone according to claim 1, is characterized in that, described acid strip film band and alkaline strip film band also comprise more than one in plasticizer, correctives, coloring agent or stabilizing agent.
3. the membranaceous preparation of risperidone according to claim 1, is characterized in that, described acidizer is selected from citric acid, tartaric acid, fumaric acid, maleic acid, adipic acid or malic acid; Described alkaline agent is selected from sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate or calcium carbonate.
4. the membranaceous preparation of risperidone according to claim 1, is characterized in that, described risperidone loads on acid strip film band, perhaps loads on alkaline strip film band, perhaps loads on simultaneously on acid strip film band and alkaline strip film band.
5. the membranaceous preparation of risperidone according to claim 1, is characterized in that, described acid strip film band comprises the component of following percentage by weight:
Described alkaline strip film band comprises the component of following percentage by weight:
In the gross weight of described membranaceous preparation, the content of described risperidone is 1～30%.
6. the membranaceous preparation of risperidone according to claim 1, is characterized in that, described acid strip film band comprises the component of following percentage by weight:
Risperidone 5～30%;
Highly-water-soluble macromolecule filming material 50～75%;
Acidizer 2～10%;
Plasticizer 0～5%;
Correctives 5～15%;
Coloring agent 0.1～5%;
Stabilizing agent 0～1%;
Described alkaline strip film band comprises the component of following percentage by weight:
Risperidone 5～30%;
Highly-water-soluble macromolecule filming material 50～75%;
Alkaline agent 2～10%;
Plasticizer 0～5%;
Correctives 5～15%;
Coloring agent 0.1～5%;
Stabilizing agent 0～1%;
In the gross weight of described membranaceous preparation, the content of described risperidone is 5～30%.
7. the membranaceous preparation of risperidone, is characterized in that, comprises the active medicine loratadine of strip film band and load treatment effective dose thereon;
Described strip film band, comprise acid strip film band, blank tape and alkaline strip film band, described blank tape is arranged between described acid strip film band and alkaline strip film band, and be connected with described acid strip film band and alkaline strip film band respectively, described blank tape comprises the highly-water-soluble macromolecule filming material;
Described acid strip film band take the highly-water-soluble macromolecule filming material as main body, with film band weighing scale, contains 1～20% acidizer;
Described alkaline strip film band take the highly-water-soluble macromolecule filming material as main body, with film band weighing scale, contains 1～20% alkaline agent.
8. the membranaceous preparation of risperidone according to claim 7, is characterized in that, described acidizer is selected from citric acid, tartaric acid, fumaric acid, maleic acid, adipic acid or malic acid; Described alkaline agent is selected from sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate or calcium carbonate.
9. the membranaceous preparation of risperidone according to claim 7, is characterized in that, described acid strip film band, blank tape and alkaline strip film band also comprise more than one in plasticizer, correctives, coloring agent or stabilizing agent.
10. the membranaceous preparation of risperidone according to claim 9, is characterized in that, described risperidone loads on more than one in acid strip film band, blank tape or alkaline strip film band.
11. the membranaceous preparation of risperidone according to claim 7 is characterized in that, described acid strip film band comprises the component of following percentage by weight:
Described alkaline strip film band comprises the component of following percentage by weight:
Described blank tape comprises the component of following percentage by weight:
In the gross weight of described membranaceous preparation, the content of described risperidone is 1～30%.
12. according to claim 1～11 membranaceous preparations of the described risperidone of any one, it is characterized in that, described water soluble polymer filmogen comprises more than one in polyvinyl alcohol (PVA), hydroxypropyl emthylcellulose (HPMC), hydroxypropyl cellulose (HPC), polyvinylpyrrolidone (PVP), sodium alginate, CMC-Na, polyoxyethylene (PEO), Bletilla glucomannan, maltodextrin, corn starch or carrageenan.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013100564457A CN103142559A (en) | 2013-02-21 | 2013-02-21 | Risperidone film-like preparation |
| CN201310256388.7A CN103349657B (en) | 2013-02-21 | 2013-06-25 | Risperidone film-shaped preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013100564457A CN103142559A (en) | 2013-02-21 | 2013-02-21 | Risperidone film-like preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103142559A true CN103142559A (en) | 2013-06-12 |
Family
ID=48541075
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2013100564457A Pending CN103142559A (en) | 2013-02-21 | 2013-02-21 | Risperidone film-like preparation |
| CN201310256388.7A Active CN103349657B (en) | 2013-02-21 | 2013-06-25 | Risperidone film-shaped preparation |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310256388.7A Active CN103349657B (en) | 2013-02-21 | 2013-06-25 | Risperidone film-shaped preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN103142559A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107260662A (en) * | 2017-06-21 | 2017-10-20 | 南京正科医药股份有限公司 | A kind of Risperidone oral administration solution and preparation method thereof |
| CN108685876A (en) * | 2017-04-11 | 2018-10-23 | 齐鲁制药有限公司 | It is a kind of to take orally membranaceous pharmaceutical composition containing Risperidone |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10224607B4 (en) * | 2002-06-04 | 2008-03-13 | Lts Lohmann Therapie-Systeme Ag | Film-form, disintegratable preparations for drug release and process for their preparation |
| CN103099799B (en) * | 2013-02-06 | 2014-08-06 | 上海现代药物制剂工程研究中心有限公司 | Composite film-like preparation and preparation method thereof |
-
2013
- 2013-02-21 CN CN2013100564457A patent/CN103142559A/en active Pending
- 2013-06-25 CN CN201310256388.7A patent/CN103349657B/en active Active
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108685876A (en) * | 2017-04-11 | 2018-10-23 | 齐鲁制药有限公司 | It is a kind of to take orally membranaceous pharmaceutical composition containing Risperidone |
| CN108685876B (en) * | 2017-04-11 | 2022-10-04 | 齐鲁制药有限公司 | Oral film-shaped pharmaceutical composition containing risperidone |
| CN107260662A (en) * | 2017-06-21 | 2017-10-20 | 南京正科医药股份有限公司 | A kind of Risperidone oral administration solution and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103349657B (en) | 2015-04-22 |
| CN103349657A (en) | 2013-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103099799B (en) | Composite film-like preparation and preparation method thereof | |
| CN103083283B (en) | Loratadine film preparation | |
| CN103083284B (en) | Film preparation and its preparation method | |
| CN102657635B (en) | Spongy asenapine sublingual film agent with micropores and preparation method thereof | |
| CN103784426B (en) | Molten membrane of Aripiprazole mouth and preparation method thereof | |
| CN102028672B (en) | Microporous spongy film preparation and preparation method thereof | |
| CN103393624B (en) | Montelukast sodium membrane-shape preparation | |
| CN107737120A (en) | A kind of tomoxetine hydrochloride oral quick-dissolving film preparation and preparation method thereof | |
| CN101574330A (en) | Rizatriptan benzoate film agent | |
| CN103349657B (en) | Risperidone film-shaped preparation | |
| CN102309562B (en) | Preparation method of taste-masked suspension granules of Gegenqinlian decoction | |
| CN103800306B (en) | Memantine oral membrane and preparation method thereof | |
| CN107949378A (en) | For bestowing the molten film of quick-acting mouths of local anaesthesia | |
| CN102940616A (en) | Ambroxol hydrochloride oral cavity dispersion membrane agent | |
| CN101574329A (en) | Zolpidem tartrate film agent | |
| CN103356512B (en) | Benzenesulfonic acid amlodipine membranaceous preparation | |
| CN106619577A (en) | Novel loratadine oral quickly soluble film and preparation method thereof | |
| CN102641258B (en) | Spongy dextromethorphan hydrobromide film agent with micro-pore and preparation method thereof | |
| Preis | Oromucosal film preparations for pharmaceutical use-formulation development and analytical characterization | |
| CN103142608B (en) | Codeine phosphate and promethazine hydrochloride compound membranous preparation | |
| KR101546667B1 (en) | Fast dissolving oral dosage form of Sildenafil improved the property of matter and shielding a bitter taste | |
| CN101849925B (en) | Rizatriptan benzoate film agent | |
| Varshney et al. | Development and evaluation of Bio-Flexy films using a novel biopolymer from Ananas cosmosus loaded with nanosized tiagabine | |
| JEEVARAJ et al. | Formulation, design and characterization of mucoadhesive buccal film--a systematic review. | |
| Alghabban et al. | Taste masking of prifinium bromide in orodispersible tablets |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130612 |